Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quinoric is a brand-name formulation of hydroxychloroquine sulfate, a small molecule drug belonging to the 4-aminoquinoline class. Developed and marketed by Bristol Laboratories, it serves as both an antimalarial and an immunomodulatory agent. Its mechanism of action involves the alteration of lysosomal pH and interference with antigen presentation, which helps dampen autoimmune responses. It is primarily indicated for the treatment of rheumatoid arthritis, systemic and discoid lupus erythematosus, and certain light-sensitive dermatological conditions. In pediatric patients, it is also used for juvenile idiopathic arthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Quinoric.